Abstract
Treatment for mNSCLC is driven by the presence of oncogenic genomic mutations. Establishing histological subtype with tissue biopsy and identification of mutations via tissue next-generation sequencing (NGS) can guide treatment decisions. Adding Plasma NGS to Tissue NGS (Tissue NGS Reflex-to-Plasma NGS) can help in identifying appropriate patients when tissue biopsy may not be feasible. This study compares Tissue NGS Reflex-to-Plasma NGS versus Tissue NGS-Only strategies for identifying patients with mNSCLC with actionable mutations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.